Taming dendritic cells with TIM-3: Another immunosuppressive strategy used by tumors

Immunotherapy

Volumn 4, Issue 12, 2012, Pages 1795-1798

  Patel, Jaina ^a   Bozeman, Erica N ^a   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antitumor immunity; galectin 9; HMGB; immune suppression; TADCs; TIM 3; tumor Associated dendritic cells; tumors

Indexed keywords

DNA VACCINE; HIGH MOBILITY GROUP B1 PROTEIN; LYMPHOCYTE MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN T CELL IMMUNOGLOBULIN MUCIN DOMAIN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; ENDOSOME; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; HMGB1 PROTEIN; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; IMMUNITY, INNATE; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROTEIN BINDING; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84871238201     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.126     Document Type: Article

References (12)

1. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 12, 479-491 (2012).
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
3. Longhi MP, Trumpfheller C, Idoyaga J et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 589-1602 (2009).
4. Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169, 375-383 (2002).
5. Monney L, Sabatos CA, Gaglia JL et al. Th1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541 (2002).
6. Moorman JP, Wang JM, Zhang Y et al. TIM-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J. Immunol. 189, 755-766 (2012).
7. Jones RB, Ndhlovu LC, Barbour JD et al. TIM-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205, 2763-2779 (2008).
8. Hafler DA, Kuchroo V. TIMs: central regulators of immune responses. J. Exp. Med. 205, 2699-2701 (2008).
9. Fourcade J, Sun Z, Benallaoua M et al. Upregulation of TIM-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
10. Anderson AC, Anderson DE, Bregoli L et al. Promotion of tissue inflammation by the immune receptor TIM-3 expressed on innate immune cells. Science 318, 1141-1143 (2007).
11. Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842 (2012).
12. Nagahara K, Arikawa T, Oomizu S et al. Galectin-9 increases TIM-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-TIM-3 interactions. J. Immunol. 181, 7660-7669 (2008).